Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-08-01 08:00 am Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | ADAR1 Capital Management LLC | 138,641 10.500% | 138,641 (New Position) | View |
| 2024-05-17 5:07 pm Unchanged | 13G | PIERIS PHARMACEUTICALS INC. PIRS | BIOTECHNOLOGY VALUE FUND L P | 257,622 19.500% | 0 (Unchanged) | View |
| 2024-05-17 5:07 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | BIOTECHNOLOGY VALUE FUND L P | 257,622 19.500% | 257,622 (New Position) | View |
| 2024-02-14 4:37 pm Sale | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Aquilo Capital Management LLC | 1,126,761 1.100% | -4,552,876 (-80.16%) | View |
| 2024-02-14 1:12 pm Sale | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Checkpoint Capital L.P. | 0 0.000% | -4,938,486 (Position Closed) | View |
| 2024-02-14 09:19 am Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Lynx1 Capital Management LP | 9,775,849 9.900% | 4,147,264 (+73.68%) | View |
| 2024-02-02 09:59 am Sale | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Soleus Capital Master Fund L.P. | 0 0.000% | -4,000,000 (Position Closed) | View |
| 2023-08-17 4:49 pm Unchanged | 13D | PIERIS PHARMACEUTICALS INC. PIRS | BIOTECHNOLOGY VALUE FUND L P | 20,609,863 20.800% | 0 (Unchanged) | View |
| 2023-06-09 5:40 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Checkpoint Capital L.P. | 4,938,486 6.000% | 4,938,486 (New Position) | View |
| 2023-05-22 4:47 pm Purchase | 13D | PIERIS PHARMACEUTICALS INC. PIRS | BIOTECHNOLOGY VALUE FUND L P | 20,609,863 22.000% | 12,915,803 (+167.87%) | View |
| 2023-02-14 4:06 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Lynx1 Capital Management LP | 5,628,585 7.600% | 1,803,966 (+47.17%) | View |
| 2023-02-14 11:28 am Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Aquilo Capital Management LLC | 5,679,637 7.500% | 1,356,349 (+31.37%) | View |
| 2023-02-13 8:14 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | BIOTECHNOLOGY VALUE FUND L P | 7,694,060 9.990% | 287,417 (+3.88%) | View |
| 2023-02-10 4:20 pm Unchanged | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Seagen Inc. SGEN | 3,706,174 5.000% | 0 (Unchanged) | View |
| 2023-02-10 10:22 am Unchanged | 13G | PIERIS PHARMACEUTICALS INC. PIRS | ASTRAZENECA PLC AZN | 3,584,230 4.800% | 0 (Unchanged) | View |
| 2023-01-27 5:02 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Soleus Capital Master Fund L.P. | 4,000,000 5.400% | 3,000,000 (+300.00%) | View |
| 2023-01-26 5:01 pm Sale | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Soleus Capital Master Fund L.P. | 1,000,000 1.300% | -2,884,868 (-74.26%) | View |
| 2022-10-24 4:57 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Lynx1 Capital Management LP | 3,824,619 5.100% | 3,824,619 (New Position) | View |
| 2022-02-14 3:20 pm Sale | 13G | PIERIS PHARMACEUTICALS INC. PIRS | Aquilo Capital Management LLC | 4,323,288 5.900% | -479,003 (-9.97%) | View |
| 2022-02-14 1:56 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC. PIRS | BIOTECHNOLOGY VALUE FUND L P | 7,406,643 9.990% | 1,805,061 (+32.22%) | View |